obesity drug news today glp-1 october 27 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 Popular GLP-1 medications may have

It's the medicine my body needed," Williams said

According to the FDA's press release it agreed to approve the drug for obesity based on three randomised, double-blind, placebo-controlled trials during which more than 2,600 patients received Wegovy for up to 68 weeks and more than 1,500 patients received placebo (US FDA 2021)

Nucleic Acids Research

Lincoff AM, SELECT Trial Investigators

The compounding issue and preventing poor practices The presentation from Zach Zalewski, Strategic Director at the United States Pharmacopeia, focused on compounding primarily regulatory policies, litigation and drug quality issues

Novo and Lilly are forging tie-ups with telehealth firms to offer the drugmakers GLP-1s at a lower cash-pay price so long as they do not sell compounded versionsa major incentive for many telehealth companies to stop providing compounded GLP-1s